Literature DB >> 21802166

Divergent actions by inhibitors of DP IV and APN family enzymes on CD4+ Teff cell motility and functions.

Aliza Biton1, Siegfried Ansorge, Ute Bank, Michael Täger, Dirk Reinhold, Stefan Brocke.   

Abstract

Dipeptidyl peptidase IV (DP IV)/CD26 and aminopeptidase N (APN)/CD13 family enzymes control T cell functions. We have previously defined these peptidases as targets to treat autoimmune disease, but the underlying mechanism is unclear. Here, we determined the effect of enzymatic inhibitors on chemotaxis by CD4+ effector T (Teff) cells. Exposure of Teff cells to the inhibitor of DP IV activity, Lys[Z(NO2)]-pyrrolidide (LZNP) and the inhibitor of APN activity, actinonin has no effect on chemotaxis or unstimulated cell migration, even at high inhibitor concentrations. LZNP and actinonin also fail to suppress migration of unfractionated lymph node cells, excluding paracrine action through other leukocyte subsets. In contrast, inhibition of DP IV and APN activities selectively suppresses lymphocyte functions including proliferation and production of the T helper type (Th)1 cytokine IFN-γ, the Th17 cytokine IL-17, as well as TNF-α, and ameliorates autoimmunity in vivo. The present results combined with previous studies suggest that LZNP and actinonin do not prevent migration of pathogenic Teff cells into target tissues, but rather suppress disease through inhibitor induced release of TGF-β by T cells at the site of inflammation.
Copyright © 2011 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21802166     DOI: 10.1016/j.imbio.2011.07.001

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  5 in total

Review 1.  CD13/Aminopeptidase N Is a Potential Therapeutic Target for Inflammatory Disorders.

Authors:  Chenyang Lu; Mohammad A Amin; David A Fox
Journal:  J Immunol       Date:  2020-01-01       Impact factor: 5.422

2.  Sarcoid-like lung granulomas in a hemodialysis patient treated with a dipeptidyl peptidase-4 inhibitor.

Authors:  Ken-Ei Sada; Jun Wada; Hiroshi Morinaga; Shigeyuki Tuchimochi; Mayu Uka; Hirofumi Makino
Journal:  Clin Kidney J       Date:  2014-01-20

Review 3.  The Role of PDE8 in T Cell Recruitment and Function in Inflammation.

Authors:  Paul M Epstein; Chaitali Basole; Stefan Brocke
Journal:  Front Cell Dev Biol       Date:  2021-04-16

4.  Treatment of Experimental Autoimmune Encephalomyelitis with an Inhibitor of Phosphodiesterase-8 (PDE8).

Authors:  Chaitali P Basole; Rebecca K Nguyen; Katie Lamothe; Puja Billis; Mai Fujiwara; Amanda G Vang; Robert B Clark; Paul M Epstein; Stefan Brocke
Journal:  Cells       Date:  2022-02-14       Impact factor: 6.600

5.  Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8⁺T Effector Memory Subset.

Authors:  Núria Alonso; María Teresa Julián; Jorge Carrascal; Roger Colobran; Irma Pujol-Autonell; Silvia Rodriguez-Fernández; Aina Teniente; Marco Antonio Fernández; Antoni Miñarro; María Carmen Ruiz de Villa; Marta Vives-Pi; Manel Puig-Domingo
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.